BRIEF published on 11/13/2025 at 07:35, 1 month 28 days ago Dermapharm Maintains Stability Amid Portfolio Adjustments Growth And Earnings Branded Pharmaceuticals Dermapharm 2025 Financial Results Portfolio Restructuring
PRESS RELEASE published on 11/13/2025 at 07:30, 1 month 28 days ago Stable earnings despite portfolio adjustment - 2025 guidance confirmed, strong growth in branded pharmaceuticals Dermapharm Holding SE reports stable earnings despite portfolio adjustments in Q3 2025, confirms 2025 guidance and strong growth in branded pharmaceuticals Pharmaceuticals Growth Earnings Dermapharm Holding SE Portfolio Adjustment
BRIEF published on 08/26/2025 at 07:35, 4 months 16 days ago Dermapharm Reports Stable Business in H1 2025 and Q2 EBITDA Growth Financial Results EBITDA Growth Revenue Stability Branded Pharmaceuticals Dermapharm Performance
PRESS RELEASE published on 08/26/2025 at 07:30, 4 months 16 days ago Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter Dermapharm confirms stable business development in H1 2025 with EBITDA growth in Q2. Full-year guidance for 2025 reiterated. Branded pharmaceuticals main growth driver Revenue Pharmaceuticals EBITDA Growth Dermapharm H1 2025
BRIEF published on 08/12/2025 at 07:35, 4 months 30 days ago Dermapharm Holding SE Continues Growth in Q2 2025 Revenue Forecast EBITDA Growth Branded Pharmaceuticals Dermapharm Q2 2025 Performance
PRESS RELEASE published on 08/12/2025 at 07:30, 4 months 30 days ago Dermapharm Holding SE remains on projected growth trajectory in Q2 2025 Dermapharm Holding SE reports Q2 2025 results in line with expectations. Confirms full-year guidance of EUR 1,160–1,200 million revenue and EUR 322–332 million EBITDA Pharmaceuticals EBITDA Growth Dermapharm Holding SE Full-year Guidance Q2 2025 Results
BRIEF published on 06/26/2025 at 17:48, 6 months 15 days ago Dermapharm Holding SE Approves EUR 0.90 Dividend Per Share Sustainability Dividend AGM Financial Outlook Dermapharm
PRESS RELEASE published on 06/26/2025 at 17:43, 6 months 15 days ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.90 per share Dermapharm Holding SE's Annual General Meeting approves divident distribution of EUR 0.90 per share for 2024, confirms 2025 outlook and ratifies Board actions Annual General Meeting Financial Year 2024 Dividend Distribution Dermapharm Holding SE EUR 0.90 Per Share
BRIEF published on 05/15/2025 at 07:35, 7 months 27 days ago Dermapharm Holding SE Meets Q1 2025 Expectations, Reinforces Full-Year Forecast Revenue Growth Full-year Guidance EBITDA Decline Branded Pharmaceuticals Dermapharm Q1 2025
PRESS RELEASE published on 05/15/2025 at 07:30, 7 months 27 days ago Dermapharm Holding SE performs in line with projections in Q1 2025, confirms full-year guidance Dermapharm Holding SE reports Q1 2025 results in line with projections, confirming full-year guidance. Revenue increases by 1.2% year-on-year to EUR 302.4 million Adjusted EBITDA Revenue Growth Dermapharm Holding SE Full-year Guidance Q1 2025 Results
Published on 01/10/2026 at 05:10, 1 day 19 hours ago Sekur Private Data Ltd. Announces Non-Brokered Private Placement
Published on 01/10/2026 at 00:45, 1 day 23 hours ago Digi Power X Announces Entry into Settlement Agreement
Published on 01/09/2026 at 23:30, 2 days ago Matador Technologies Announces Grant of Restricted Share Units to Management Team
Published on 01/09/2026 at 23:10, 2 days 1 hour ago Usha Resources and Totec Resources Provide Supplemental Disclosure for Qualifying Transaction
Published on 01/11/2026 at 22:20, 1 hour 51 minutes ago Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Published on 01/10/2026 at 21:25, 1 day 2 hours ago CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh
Published on 01/10/2026 at 13:05, 1 day 11 hours ago SeaVerse Launches World's First AI Native Platform, "All in AI Native" Leads the Forward-Looking Revolution in AI Creation
Published on 01/09/2026 at 21:55, 2 days 2 hours ago Piramal Pharma Achieves Notable Score Increase on 2025 S&P Global Corporate Sustainability Assessment (CSA)
Published on 01/09/2026 at 18:36, 2 days 5 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/09/2026 at 18:30, 2 days 5 hours ago H2 2025 half yearly report on the liquidity agreement signed with the Gilbert Dupont brokerage firm
Published on 01/09/2026 at 17:45, 2 days 6 hours ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 01/09/2026 at 17:42, 2 days 6 hours ago Aéroports de Paris SA - Shares and voting rights as of 31 December 2025
Published on 01/08/2026 at 21:00, 3 days 3 hours ago Biannual report on SEB S.A.’S liquidity agreement
